Senti Biosciences (SNTI) Institutional Ownership $2.20 -0.01 (-0.45%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$2.20 0.00 (0.00%) As of 07/8/2025 05:29 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Senti Biosciences (NASDAQ:SNTI)CurrentInstitutional OwnershipPercentage25.73%Number ofInstitutional Buyers(last 12 months)4TotalInstitutional Inflows(last 12 months)$5.73MNumber ofInstitutional Sellers(last 12 months)3TotalInstitutional Outflows(last 12 months)$17.47M Get SNTI Insider Trade Alerts Want to know when executives and insiders are buying or selling Senti Biosciences stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data SNTI Institutional Buying and Selling by Quarter Senti Biosciences Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails5/15/2025Nantahala Capital Management LLC888,000$2.98M0.1%N/A3.405% 5/15/2025Heights Capital Management Inc.750,000$2.52M1.3%N/A2.876% 2/13/2025Renaissance Technologies LLC51,600$181K0.0%N/A1.071% 2/11/2025Virtu Financial LLC13,356$47K0.0%N/A0.277% 11/14/2024NEA Management Company LLC442,615$1M0.1%-90.0%9.664% 11/7/20248VC GP I LLC253,755$573K0.8%-90.0%5.541% 10/31/2024ARK Investment Management LLC176,666$399K0.0%-88.9%3.858% 7/26/2024ARK Investment Management LLC1,585,772$438K0.0%-2.8%34.624% 2/12/20248VC GP I LLC2,537,558$1.68M1.7%N/A5.697% 1/17/2024ARK Investment Management LLC1,969,860$1.30M0.0%+7.9%4.423% Get the Latest News and Ratings for SNTI and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Senti Biosciences and its competitors with MarketBeat's FREE daily newsletter. 10/27/2023TD Asset Management Inc241,208$102K0.0%+88.4%0.542% 9/7/2023Triatomic Management LP300,533$188K0.2%+42.5%0.675% 7/10/2023ARK Investment Management LLC1,829,815$1.15M0.0%-3.8%4.143% 5/3/2023Triatomic Management LP210,883$249K0.2%+39.0%0.477% 4/17/2023ARK Investment Management LLC1,901,467$2.24M0.0%-1.3%4.305% 2/14/2023Triatomic Management LP151,675$214K0.2%+168.7%0.346% 2/13/2023Artal Group S.A.55,555$78K0.0%-94.7%0.127% 2/7/2023TD Asset Management Inc118,292$167K0.0%-12.3%0.270% 1/24/2023ARK Investment Management LLC1,925,827$2.72M0.0%-7.8%4.391% 11/15/2022Triatomic Management LP56,454$123K0.1%N/A0.129% 11/7/2022TD Asset Management Inc.134,892$285K0.0%+53.8%0.308% 11/3/2022The Manufacturers Life Insurance Company117,707$248K0.0%N/A0.269% 10/17/2022ARK Investment Management LLC2,087,696$4.53M0.0%N/A4.771% 8/11/2022Artal Group S.A.1,055,555$2.07M0.1%N/A4.450% 8/8/2022Allen Operations LLC21,443$42K0.0%N/A0.090% 8/4/2022TD Asset Management Inc.87,696$172K0.0%N/A0.370% 7/29/2022Kingfisher Capital LLC113,163$222K0.1%N/A0.477% (Data available from 1/1/2016 forward) SNTI Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of SNTI shares? During the previous two years, 9 institutional investors and hedge funds held shares of Senti Biosciences. The most heavily invested institutionals were Nantahala Capital Management LLC ($2.98M), Heights Capital Management Inc. ($2.52M), NEA Management Company LLC ($1M), 8VC GP I LLC ($573K), ARK Investment Management LLC ($399K), Triatomic Management LP ($188K), and Renaissance Technologies LLC ($181K).Learn more on Senti Biosciences' institutional investors. What percentage of Senti Biosciences' stock is owned by institutional investors? 25.73% of Senti Biosciences' stock is owned by institutional investors. Learn more on SNTI's institutional investor holdings. Which institutional investors have been buying Senti Biosciences' stock? The following institutional investors have purchased Senti Biosciences' stock in the last 24 months: 8VC GP I LLC ($2.54M), Nantahala Capital Management LLC ($888K), Heights Capital Management Inc. ($750K), ARK Investment Management LLC ($143.79K), TD Asset Management Inc ($113.17K), Triatomic Management LP ($89.65K), and Renaissance Technologies LLC ($51.60K). How much institutional buying is happening at Senti Biosciences? Institutional investors have bought a total of 1,702,956 shares in the last 24 months. This purchase volume represents approximately $5.73M in transactions. Which of Senti Biosciences' major shareholders have been selling company stock? The following institutional investors have sold Senti Biosciences stock in the last 24 months: NEA Management Company LLC ($3.98M), 8VC GP I LLC ($2.28M), and ARK Investment Management LLC ($1.45M). How much institutional selling is happening at Senti Biosciences? Institutional investors have sold a total of 7,721,595 shares in the last 24 months. This volume of shares sold represents approximately $17.47M in transactions. Related Companies Canopy Growth Major Shareholders ProQR Therapeutics Major Shareholders Nanobiotix Major Shareholders Y-mAbs Therapeutics Major Shareholders I-Mab Major Shareholders Cardiff Oncology Major Shareholders Inhibrx Biosciences Major Shareholders MediWound Major Shareholders SOPHiA GENETICS Major Shareholders Monopar Therapeutics Major Shareholders This page (NASDAQ:SNTI) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to...Brownstone Research | Sponsored$3,200 from your phone?No charts. No crypto. No stock picking. With just a regular brokerage app and Jeff Clark’s “Crossfire” meth...TradeSmith | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump Exec Order 14179 is wealth “gift” to good Americans?Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...Paradigm Press | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Senti Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Senti Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.